Skip to main content

Phyllis W. Speiser, MD

Phyllis W. Speiser, MD

Associate Professor, Institute of Molecular Medicine
Feinstein Institutes for Medical Research
Emerita Professor, Pediatrics Donald and Barbara Zucker School of Medicine
Hofstra/Northwell
New Hyde Park, NY

Related Videos

What are the challenges of optimizing therapy—even with glucocorticoids—considering that in CAH the aldosterone, androgen, and glucocorticoid pathways are coupled with one another?

What are the challenges of optimizing therapy—even with glucocorticoids—considering that in CAH the aldosterone, androgen, and glucocorticoid pathways are coupled with one another?

Can you discuss the complications of excessive glucocorticoid exposure in children, adolescents, and adults, and the impact on cardiac and metabolic morbidities? What is the rational for looking for alternatives to glucocorticoid therapy for CAH?

Can you discuss the complications of excessive glucocorticoid exposure in children, adolescents, and adults, and the impact on cardiac and metabolic morbidities? What is the rational for looking for alternatives to glucocorticoid therapy for CAH?

Can you discuss the CAHtalyst pediatric strategies aimed at understanding whether a de-coupling of the androstenedione and glucocorticoid pathways might be a solution for reducing the burden of glucocorticoid therapy?

Can you discuss the CAHtalyst pediatric strategies aimed at understanding whether a de-coupling of the androstenedione and glucocorticoid pathways might be a solution for reducing the burden of glucocorticoid therapy?

Can you discuss what monitoring and therapeutic end points—i.e., glucocorticoid sparing—were selected, and why, for the CAHtalyst trial? And what were the trial’s primary objectives?

Can you discuss what monitoring and therapeutic end points—i.e., glucocorticoid sparing—were selected, and why, for the CAHtalyst trial? And what were the trial’s primary objectives?

In phase 1 of the CAHtalyst pediatric study, did investigators demonstrate a statistically significant decrease in serum androstenedione from baseline with crinecerfont at Week 4 over baseline?

In phase 1 of the CAHtalyst pediatric study, did investigators demonstrate a statistically significant decrease in serum androstenedione from baseline with crinecerfont at Week 4 over baseline?

Can you briefly summarize how you developed your interest in CAH?

Can you briefly summarize how you developed your interest in CAH?

What can you tell us about some of the key features of the CAHtalyst pediatric trial, including retention of trial subjects, and achieving androstenedione end points in patients on crinecerfont?

What can you tell us about some of the key features of the CAHtalyst pediatric trial, including retention of trial subjects, and achieving androstenedione end points in patients on crinecerfont?

In the second phase of the CAHtalyst pediatric trial, can you discuss initiating down-titration of glucocorticoid therapy, and what levels of glucocorticoid sparing were targeted?

In the second phase of the CAHtalyst pediatric trial, can you discuss initiating down-titration of glucocorticoid therapy, and what levels of glucocorticoid sparing were targeted?

What does the landscape look like for diagnosing, assessing, and monitoring persons—adult and pediatric—who are suspected of having or have confirmed CAH?

What does the landscape look like for diagnosing, assessing, and monitoring persons—adult and pediatric—who are suspected of having or have confirmed CAH?